September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Prevalence of diabetic retinopathy in dependence on the steps of Diabetes Management Guidelines
Author Affiliations & Notes
  • Lydia Marahrens
    Center for Ophthalmology, Eberhard Karls University, Tuebingen, Germany
  • Daniel Röck
    Center for Ophthalmology, Eberhard Karls University, Tuebingen, Germany
  • Raimar Kern
    Department of Neurology, Autonomic and Neuroendocrinological Laboratory Dresden, University Hospital Carl Gustav Carus at the Dresden University of Technology, Dresden, Germany
  • Tjalf Ziemssen
    Department of Neurology, Autonomic and Neuroendocrinological Laboratory Dresden, University Hospital Carl Gustav Carus at the Dresden University of Technology, Dresden, Germany
  • Andreas Fritsche
    Department of Internal Medicine, Eberhard Karls University, Tuebingen, Germany
  • Peter Martus
    Institute of Clinical Epidemiology and applied Biostatistics, Eberhard Karls University, Tuebingen, Germany
  • Focke Ziemssen
    Center for Ophthalmology, Eberhard Karls University, Tuebingen, Germany
  • Footnotes
    Commercial Relationships   Lydia Marahrens, None; Daniel Röck, Novartis (F); Raimar Kern, Bayer-Healthcare (R), Biogen Idec (R), Genzyme (R), Merck Serono (R), Novartis (R), Teva (R); Tjalf Ziemssen, Almirall (R), Bayer-Schering (R), Bayer-Schering (C), Biogen Idec (R), Biogen Idec (C), Deutsche Diabetes Stiftung (F), Genzyme (R), GSK (R), Hertie Foundation (F), Merck Serono (R), MSD (R), Novartis (R), Novartis (C), Sanofi-Aventis (R), Teva (R), Teva (C), the Robert Pfleger Foundation(F), Roland Ernst Foundation (F); Andreas Fritsche, None; Peter Martus, None; Focke Ziemssen, Alcon (R), Alimera (C), Allergan (R), Allergan (C), Bayer (R), Bayer (C), Biogen (R), Biogen (C), Novartis (R), Novartis (F), Novartis (C)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 1597. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Lydia Marahrens, Daniel Röck, Raimar Kern, Tjalf Ziemssen, Andreas Fritsche, Peter Martus, Focke Ziemssen; Prevalence of diabetic retinopathy in dependence on the steps of Diabetes Management Guidelines. Invest. Ophthalmol. Vis. Sci. 2016;57(12):1597.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Our aim was to assess the differences in prevalence of diabetic retinopathy between the treatment groups as defined by the steps of management guidelines.

Methods : The DiabCheck® study was a non-interventional cross-sectional study of 810 adults recruited in 3 secondary diabetes care centers during a period of 4 month. All patients of the investigator initiated study were included after confirmed diagnosis of diabetes and underwent a comprehensive eye examination. 508 patients with Type 2 Diabetes mellitus (T2DM) were divided into 4 distinct groups according to the recommendations of the German Disease Management Guideline on the Treatment of T2DM, also in accordance with the joint statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD): 1) the non-pharmacological basic therapy group (BASIC) characterized by healthy eating, weight control and increased physical activity, 2) the monotherapy group (MONO), 3) the dual therapy group (DUAL) and 4) the combination therapy group with insulin strategies in combination with non-insulin agents (COMBI).
For categorical outcomes, χ2-test was used to test for significant differences between the therapy groups. For continuous outcomes, significant differences were evaluated with the one-way ANOVA (α=0.05).

Results : The prevalence of diabetic retinopathy was 3.2% within the BASIC group (69/508), 1.4% in the MONO (69/508), 7.6% in the DUAL and 15.8% in the COMBI group (p<0.001). Corresponding to the four groups, the mean diabetes duration showed a continuous increase: 3.6 yrs (95-CI: 2.1, 5.0) (BASIC), 6.0 yrs. (95-CI: 4.8, 7.3) (MONO), 9.5 yrs. (95-CI: 8.3, 10.7) (DUAL) and 15.9 yrs (95-CI: 14.8, 16.9) (COMBI) (p<0.001). With increasing diabetes duration patients tended to climb in the treatment steps. Thus, after 20 yrs. the large majority of T2DM were in the COMBI group

Conclusions : If there is uncertainty over the duration of disease, the step of escalating management might be used to describe the patient’s risk of developing diabetic retinopathy. This could further enhance the risk awareness of primary care physicians and patients.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×